13th Annual Advances in Oncology 2012
Saturday, September 22nd, 2012
Sheraton Sacramento
Sacramento, CA

Register online at www.meccinc.com
or Mail to: MEC, Inc. 1550 S Dixie Hwy # 202, Coral Gables, FL 33146
or FAX to 305/675-2718.

Name _____________________________________________ Degree _____________
Address _______________________________________________________________
City ____________________________ State ___________________ Zip ___________
Telephone (___)__________________________ FAX (____)____________________
Email address __________________________________________________________
Specialty______________________________________________________________

Type of Practice:        q Private        q Academic       q Hospital       q Resident/Fellow

Registration fee: $75 PHYSICIANS/NURSES/FELLOWS/RESIDENTS
PHYSICIAN ASSISTANTS/OFFICE STAFF
$150 INDUSTRY PROFESSIONALS

Enclosed is my check in the i/a/o of _____ for registration of this course.

I authorize MECC to charge my credit card i/a/o $_______ for registration of this
course using the following credit card.

Name on Card __________________________________ Exp. Date______________
Card number __________________________________________________________
Authorized signer ______________________________________________________

If you require special assistance or have specific dietary requirements, please contact
MECC, Inc. no later than August 22, 2012 via email at tvalls@meccinc.com.

Registration fee includes admission to Saturday scientific presentations and handout
materials. Refunds must be provided in writing prior to August 22, 2012. After August
22, 2012, No Refunds will be provided.

Register online at www.meccinc.com

For more information contact:
CONFERENCE MANAGEMENT
MEC, Inc. 1550 S Dixie Highway Suite 202, Coral Gables, FL 33146
Telephone: 305/663-1628 Office Fax 305/675-2718
Or visit our website at www.meccinc.com
Email: tvalls@meccinc.com

CONFERENCE DIRECTORS
Helen K. Chew, M.D., FACP
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA

Primo Lara, Jr., M.D.
Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA

PRESENTED BY
UC DAVIS
COMPREHENSIVE
CANCER CENTER

SPONSORED BY:
THE MEDICAL EDUCATOR CONSORTIUM
The 13th Annual Advances in Oncology program will bring together academic and community oncologists for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. The program is designed to update physicians and other health care providers on recent advances and new diagnostic and treatment modalities in hematologic, breast, lung, gastrointestinal, and genitourinary cancers. This course is intended for physicians and other health care providers, including medical, surgical, and radiation oncologists, nurses, physician assistants, pharmacists and other interested health care professionals. The conference will also include multidisciplinary sessions from national oncology leaders and case-based panel discussions involving academic and community oncologists.

EDUCATIONAL OBJECTIVES

At the conclusion of this symposium, you should be able to:
1. Discuss advances in prognostic and predictive biomarkers and potential applications in therapeutic decision making.
2. Integrate targeted and traditional therapeutic modalities in the treatment of cancer.
3. Assess newly validated treatment options for patients with solid tumors or hematologic malignancies.
4. Apply data from recent clinical trials to determine the optimal course of therapy in defined patient populations, with emphasis on novel multi-agent therapies and multi-targeted tyrosine kinase inhibitors, and bone-targeting agents, among others.

NEEDS ASSESSMENT

The diagnosis, risk stratification, and multi-modality state-of-the-art treatment of hematologic and solid malignancies are rapidly evolving. The development of molecular prognostic assays and new targeted therapies provides promising tools for personalized medicine. As a result of prior course participant evaluations and needs assessment surveys, the need for cutting edge information on prognostic markers and appropriate application of novel therapies has been identified. This year’s conference will specifically address these needs in the common malignancies identified by past participants as essential to their practice, including gastrointestinal, hematologic, and genitourinary cancers. The timing of this meeting and fall allows for the latest findings in clinical cancer research from major hematology and oncology conferences to be presented and discussed. This educational activity also meets a unique need for the Northern California Sacramento Valley to provide a group of networked and collaborating oncologists a forum to discuss the most recent developments in oncology care in the context of local treatment approaches, patient populations, and open clinical trials.

The course is designed to change physician competence in oncology care. State of the art lectures and panel discussions from local and national oncologists will provide ample discussions on the applications and challenges of new prognostic tools and targeted and cytotoxic therapies. Pre-test and post-test audience response systems (evaluations) will be used to outcome measures.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS

The Medical Educator Consortium designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. Authors that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational Activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credit™, and has been taken within the appropriate time frames.

SPEAKER BIOGRAPHIES

Mehrad Abedi, M.D. Associate Professor of Medicine Division of Hematology and Oncology UC Davis Comprehensive Cancer Center Sacramento, CA

Vijay Khatri, M.D. Professor of Surgery UC Davis Comprehensive Cancer Center Sacramento, CA

Dinesh Kotak, M.D. Kaiser Permanente Sacramento, CA

Luko Laptalo, M.D. Sacramento Center for Hematology and Oncology Sacramento, CA

Primo N. Lara, Jr., M.D. Professor of Medicine Division of Hematology and Oncology UC Davis Comprehensive Cancer Center Sacramento, CA

Mingli Li, M.D. Sierra Hematology and Oncology Stockton, CA

Gilbert Mandell, M.D. Permanente Medical Group Sacramento, CA

Aminder Mehdi, M.D. Stockton Hematology and Oncology Stockton, CA

Akifjhumkar Puthalath, M.D. Stockton Hematology and Oncology Stockton, CA

Tom Semrad, M.D. Assistant Professor Division of Hematology and Oncology UC Davis Comprehensive Cancer Center Sacramento, CA

Samer Shihabi, M.D. Sacramento Center for Hematology and Oncology Sacramento, CA

Joseph Tuscano, M.D. Professor of Medicine Division of Hematology and Oncology UC Davis Comprehensive Cancer Center Sacramento, CA

Tod Wun, M.D. Professor of Medicine and Division Chief Division of Hematology and Oncology UC Davis Comprehensive Cancer Center Sacramento, CA

Evan Yu, M.D. Assistant Professor University of Washington Seattle Cancer Care Alliance Seattle, WA

ACADEMY AND PANELISTS

7:30 am Registration, continental breakfast, visit exhibits
8:00 am Welcome Remarks Helen K. Chew, M.D. and Primo Lara, M.D.
8:05 am Pre-session Survey
8:10 am Keynote Lecture, The Lois O’Grady Lectureship “Advances in Stem Cell Transplantation in Hematologic Malignancies” Steve Forman, M.D., Professor of Medicine
8:50 am “Incorporating Novel Therapies in Breast Cancer: from mTOR Inhibitors to Bisphosphonates; What’s Next?” Helen K. Chew, M.D. University of California Davis
9:10 am Panel Discussion: Multidisciplinary Breast Cancer Management Moderator: Helen K. Chew, M.D.
9:50 am Q&A
10:00 am "Personalizing Therapy in Lung Cancer: where EGFR and ALK fit in" Karen Kelly, M.D. University of California Davis
10:20 am Panel Discussion: Multidisciplinary Lung Cancer Management Moderator: Primo Lara, M.D.
11:10 am Break refreshment, visit exhibits
11:25 am Panel Discussion: Multidisciplinary Breast Malignancies" Tom Semrad, M.D. University of California Davis
11:45 am Panel Discussion: Multidisciplinary GI Malignancy Management Moderator: Tom Semrad, M.D.
12:25 pm Q&A
12:35 pm Adjourn for Lunch
1:30 pm "New Therapeutic Options in Advanced Genitourinary Cancers" Evan Yu, M.D.
1:50 pm “New Therapeutics in Hematologic Malignancies” Joseph Tuscano, M.D. University of California Davis
2:10 pm Panel Discussion:Benign and Malignant Hematology Moderator: Joseph Tuscano, M.D.
2:50 pm Q&A
3:00 pm Post-session Survey/Closing Remarks Helen K. Chew, M.D.